Monitor the progression of this patent infringement case toward summary judgment or trial. The Markman ruling provides some clarity on claim scope but does not resolve infringement or validity. The deferred indefiniteness arguments could become material if they result in claim invalidation.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $309.64entry
- T+1 · yesterday +0.35%α +2.26% · $310.72
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The District of New Jersey issued a Markman claim construction opinion in Treace Medical Concepts v. Stryker Corp. The court adopted a mix of plaintiff and defendant constructions across 15 disputed terms in nine patents covering bunion correction systems. The ruling is an interlocutory step in the patent infringement case; no damages were awarded and no injunction was issued. For Stryker, the outcome is neutral, the case continues with some claim terms construed favorably to each side.
Court Ruling Details
Key Facts
- Court issued Markman claim construction opinion in Treace Medical Concepts v. Stryker Corp. et al.
- Fifteen disputed terms across nine patents (US 9,622,805; 10,874,446; 11,039,873; 11,116,558; 11,602,386; 11,602,387; 11,911,085; 11,937,849; 11,950,819) were construed.
- Court adopted plaintiff's construction for 'bone positioning guide', 'guide surface' and 'guiding surface' in the '849 Patent, and 'the bone positioning guide is fabricated from a radiolucent material'.
- Court adopted defendants' construction for 'guide surface' in the '387 Patent, 'bone engagement member', 'tip', and 'system'.
- Court adopted its own construction for 'main body member'.
- Court deferred indefiniteness arguments on seven terms to summary judgment or trial.
- No damages awarded, no injunction issued; the case remains pending.
Financial Impact
No financial impact stated in the ruling. The case is at an early claim construction stage with no damages or injunction.
Risk Factors
- Adverse final judgment on patent infringement could result in damages or an injunction on Stryker's LapiFuse and PROstep bunion correction products.
- Indefiniteness challenges to seven claim terms remain pending and could narrow or invalidate asserted claims at summary judgment or trial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-022d374c0d-SYK |
Track record
29 reports on SYK
5 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +23.40% at T+20 after the Oct 7, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 12, 20266d ago Court Ruling Neutral 3/10 Viewing Entry $309.64 Now $310.72 +0.35% settles Dec 14
- Nov 9, 20268d ago 8-K Neutral 2/10 Entry $324.29 Now $310.72 −4.18% settles Dec 9
- Nov 5, 202612d ago 144 Neutral 3/10 Entry $325.87 Now $310.72 −4.65% settles Dec 7
- Nov 4, 202613d ago S-3ASR Neutral 3/10 Entry $335.08 Now $310.72 −7.27% settles Dec 4
- Nov 3, 202614d ago Institutional Cluster Mixed 3/10 Entry $310.55 Now $310.72 +0.05% settles Dec 2
- Oct 29, 202619d ago 8-K Bearish 6/10 No price data
- Oct 29, 202619d ago Press Release Bearish 6/10 Entry $291.86 Now $310.72 −6.46% settles Nov 30
- Oct 26, 202622d ago Press Release Neutral 4/10 Entry $306.13 Now $310.72 +1.50% settles Nov 23
- Oct 20, 202629d ago PTAB Trial Bearish 5/10 Entry $297.60 Now $310.72 −4.41% settles Nov 18
- Oct 7, 20265w ago ANALYST-UPGRADE Bullish 4/10 Entry $275.25 to $339.65 Now $310.72 +12.89% ▲ +23.40% +24.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers